Golotimod (SCV 07) 一种具有抗菌活性的免疫调节肽，可显著提高抗结核研究的功效，刺激胸腺和脾细胞增殖，并改善巨噬细胞功能。Golotimod 抑制STAT3信号传导并调节接受放疗或放疗与顺铂联合用药的动物模型中口腔粘膜炎的持续时间和严重程度。Golotimod 具有用于研究复发性生殖器单纯疱疹病毒 2 型 (HSV-2)的潜力。
| 生物活性 | Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibitsSTAT3signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3]. |
| IC50& Target[2] | |
体内研究
(In Vivo) | Golotimod (SCV-07) (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs[1].
Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters[3].
| Animal Model: | Female Hartley guinea pigs (250-300 g) infected HSV-2[1] | | Dosage: | 100 μg/kg | | Administration: | Oral gavage or subcutaneous injection; 5 days | | Result: | Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07. |
| Animal Model: | Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis[3] | | Dosage: | 10, 100 μg/kg or 1 mg/kg | | Administration: | Subcutaneous injection; once or twice a day from days 1 to 20 | | Result: | Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg.
Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com